Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O. Box: 19395-4763, Tehran, 1985717413, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Cardiovasc Diabetol. 2022 Dec 3;21(1):269. doi: 10.1186/s12933-022-01707-1.
To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III), and Joint Interim Statement (JIS) criteria.
The study population included a total of 5,079 participants (2,785 women) aged ≥ 40 years, free of cardiovascular disease (CVD) at baseline. Participants were followed for incident SCD annually up to 20 March 2018. Multivariable Cox proportional hazards regression models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MetS and its components for incident SCD.
The prevalence of MetS ranged from 27.16% to 50.81%, depending on the criteria used. Over a median of 17.9 years of follow-up, 182 SCD events occurred. The WHO, IDF, and JIS definitions were strong predictors of SCD with multivariable-adjusted HRs (95% CI) of 1.68 (1.20-2.35), 1.51 (1.12-2.03), and 1.47 (1.08-1.98), respectively; these associations significantly attenuated after further adjustment for MetS components. MetS by the ATP III definition was not associated with the risk of SCD after controlling for antihypertensive, glucose-lowering, and lipid-lowering medication use. Among the components of MetS, high blood pressure (WHO definition), high waist circumference (using the national cutoff of ≥ 95 cm), and high glucose component by the JIS/IDF definitions remained independent predictors of SCD with HRs of 1.79 (1.29-2.48), 1.46 (1.07-2.00), and 1.52 (1.12-2.05), respectively.
The constellation of MetS, except for when defined with ATP III definition, is a marker for identifying individuals at higher risk for SCD; however, not independent of its components. Among MetS components, abdominal obesity using the population-specific cutoff point, high glucose component (JIS/IDF definitions), and high blood pressure (WHO definition) were independent predictors of SCD.
根据世界卫生组织(WHO)、国际糖尿病联合会(IDF)、美国成人治疗小组 III(ATP III)和联合临时声明(JIS)标准,评估不同代谢综合征(MetS)定义及其成分对伊朗人群心源性猝死(SCD)风险的影响。
研究人群包括共 5079 名年龄≥40 岁的参与者(2785 名女性),基线时无心血管疾病(CVD)。每年对参与者进行一次 SCD 事件的随访,直至 2018 年 3 月 20 日。采用多变量 Cox 比例风险回归模型来估计 MetS 及其成分与 SCD 发生率的风险比(HRs)和 95%置信区间(CIs)。
根据使用的标准,MetS 的患病率从 27.16%到 50.81%不等。在中位数为 17.9 年的随访期间,发生了 182 例 SCD 事件。WHO、IDF 和 JIS 定义是 SCD 的强预测因子,多变量调整后的 HR(95%CI)分别为 1.68(1.20-2.35)、1.51(1.12-2.03)和 1.47(1.08-1.98);这些关联在进一步调整 MetS 成分后显著减弱。ATP III 定义的 MetS 在控制降压、降糖和降脂药物使用后与 SCD 风险无关。在 MetS 的成分中,高血压(WHO 定义)、高腰围(采用≥95cm 的全国截断值)和 JIS/IDF 定义的高血糖成分仍然是 SCD 的独立预测因子,HR 分别为 1.79(1.29-2.48)、1.46(1.07-2.00)和 1.52(1.12-2.05)。
除了使用 ATP III 定义外,MetS 的组合是识别 SCD 风险较高个体的标志物;然而,它不是其成分的独立标志物。在 MetS 成分中,使用人群特异性截断值的腹型肥胖、高血糖成分(JIS/IDF 定义)和高血压(WHO 定义)是 SCD 的独立预测因子。